Abstract 1519P
Background
Fruquintinib (F, a highly selective VEGFR inhibitor) plus sintilimab (S, an anti-PD-1 monoclonal antibody) showed promising antitumor activity in both pre-clinical and clinical studies. Here, we reported the results of F plus S from a gastric cancer (GC) cohort in an open-label, multicenter, single-arm phase II study in China.
Methods
Advanced gastric or GEJ adenocarcinoma pts with PD-L1 status of CPS ≥1, who had no prior systemic therapy or had failed at least first-line treatment were enrolled. Eligible pts received F (5 mg, 2 weeks on/1 week off, orally, once daily) plus S (200 mg, IV, every 3 weeks) in 21-day cycles, until disease progression or unacceptable toxicity. Treatment of S was allowed for up to 24 months (mo). The primary endpoint was ORR per RECIST v1.1.
Results
As of February 28, 2023, 27 pts were enrolled and received F plus S, including 20 treatment-naive pts (i.e.: 1st -line pts), and 7 pts with prior treatment (i.e.: ≥ 2nd-line pts). Median (range) age was 63.71 (35.8, 74.6) years. There were 8 (29.6%), 9 (33.3%), and 8 (29.6%) pts with PD-L1 status of 1≤ CPS <5, 5≤ CPS<10, and 10≤ CPS, which was tested by the central lab, respectively. Median duration of treatment of F and S were 6.90 and 7.13 months. Among tumor evaluable pts (N=18 for 1st -line pts, N=6 for ≥ 2nd-line pts), confirmed ORRs were 72.2% and 33.3% in 1st -line pts and ≥ 2nd-line pts, respectively; clinical responses correlated with level of PD-L1 status. DCRs were 100% and 83.3% in 1st -line pts and ≥ 2nd-line pts; median TTR reached 2.7 mo and 2 mo in 1st -line pts and ≥ 2nd-line pts. 9-month PFS rates were 63.8% and 50.0% in 1st -line pts and ≥ 2nd-line pts. Median PFS and OS were not mature. Common (≥20%) treatment-related treatment-emergent adverse events included proteinuria (48.1%), hypothyroidism (40.7%), aspartate aminotransferase increased (25.9%), alanine aminotransferase increased (22.2%), hypertension (22.2%), and weight decreased (22.2%).
Conclusions
F plus S provided favourable efficacy and manageable toxicity profile in pts with advanced gastric or GEJ adenocarcinoma, especially for pts who cannot tolerate chemotherapy.
Clinical trial identification
NCT03903705.
Editorial acknowledgement
Editorial support was provided by Haoyun Shi of HUTCHMED Limited.
Legal entity responsible for the study
HUTCHMED Limited.
Funding
HUTCHMED Limited.
Disclosure
P. Lu; H. Shi; P. Tan; S. Fan; M. Shi; W. Su: Financial Interests, Personal, full or part-time employment: HUTCHMED Limited. All other authors have declared no conflicts of interest.
Resources from the same session
1564P - Gut microbiome and metabolome are associated with the response to chemoradiotherapy in patients with esophageal cancer
Presenter: Mingqiang Lin
Session: Poster session 21
1565P - ERCC1 gene polymorphism influences overall survival in early oesophageal cancer: Results from the phase III MRC OEO2 randomised controlled trial
Presenter: Georgina Keogh
Session: Poster session 21
1566P - Clinical relevance of circulating tumor DNA in HER2 -positive advanced gastric cancer: Results from phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High)
Presenter: Hiroki Osumi
Session: Poster session 21
1567P - The effect of SGLT2i and DPP4i on new-onset gastric cancer and gastric diseases in type 2 diabetes mellitus: A population-based cohort study
Presenter: Hou In Chou
Session: Poster session 21
1568P - Establishment of a platform to predict radiation sensitivity in organoids derived from esophageal cancer patients
Presenter: Ga Yeon Kim
Session: Poster session 21